|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||2.4450 - 2.4550|
|52-week range||2.4450 - 2.4550|
|Beta (5Y monthly)||2.24|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
At this time, I would like to welcome everyone to the Arbutus Biopharma 2022 second quarter financial results and corporate update. Good morning, everyone, and thank you for joining our second quarter 2022 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr.
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).